Kidney Cancer: An Overview of Current Therapeutic Approaches.

Kidney Cancer: An Overview of Current Therapeutic Approaches. Urol Clin North Am. 2020 Nov;47(4):419-431 Authors: Chowdhury N, Drake CG Abstract The management of metastatic renal cell carcinoma (RCC) has evolved rapidly in recent years with several immunotherapy-based combinations of strategies approved as first-line therapies. Targeted strategies, including systemic antiangiogenesis agents and immune checkpoint blockade, form the basis of a therapeutic approach. With rising rates of recurrence after first-line treatment, it is increasingly important to not only adopt a personalized treatment plan with minimal adverse events but also develop predictive biomarkers for response. This review discusses currently available first-line and second-line therapies in RCC and their pivotal data, with specific focus on ongoing clinical trials in the adjuvant setting, including those involving novel agents. PMID: 33008493 [PubMed - as supplied by publisher]
Source: The Urologic Clinics of North America - Category: Urology & Nephrology Authors: Tags: Urol Clin North Am Source Type: research

Related Links:

Conclusions: This retrospective study points out that early systemic steroids administration to manage irAEs might not have a detrimental effect on patient clinical outcome in NSCLC, melanoma and RCC patients.
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
This study explored thePBRM1-associated immunological features and identified the immune-related genes (IRGs) linked toPBRM1 mutation using bioinformatics methods. A total of 37 survival IRGs associated withPBRM1 mutation in ccRCC patients were identified. To further explore the role of these IRGs in ccRCC and their association with immune status, eight IRGs with remarkable potential as individual targets were selected. An immune model that was constructed showed good performance in stratifying patients into different subgroups, showing clinical application potential compared to traditional clinical factors. Patients in th...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: RESEARCH ARTICLE Source Type: research
Anti-angiogenic agents and immunotherapy are the cornerstone of advanced/metastatic renal-cell carcinoma (mRCC) treatment. Recently, the therapeutic scenario of first-line therapy for mRCC has been completely revolutionized. The combination of the two immune checkpoint inhibitors (ICIs) nivolumab and ipilimumab (targeting PD-1 and CTLA4, respectively) yielded a significant survival advantage, compared to sunitinib, in International Metastatic RCC Database consortium (IMDC) intermediate- and poor-risk patients, but failed to improve outcomes of favorable-risk patients [1].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSIONS: This signature was proven to have a potential predictive significance for the prognosis of patients with ccRCC and the efficacy of immunotherapy.PMID:34512816 | PMC:PMC8429034 | DOI:10.1155/2021/8800358
Source: Disease Markers - Category: Laboratory Medicine Authors: Source Type: research
AbstractRenal cell carcinoma (RCC) is a highly vascularized and immunogenic tumor, being an ideal candidate for checkpoint blockade-based immunotherapy. Accordingly, checkpoint inhibitors have demonstrated clinical efficacy in patients with metastatic RCC (mRCC). Sex-specific differences in cancer immunotherapy may be explained by the interaction of sex hormone signaling, genetic and environmental factors, affecting the innate and adaptive immune response in men and women in different ways. The aim of this prospective study was to monitor for the first time changes in sex hormones including luteinizing hormone (LH), follic...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
In this report, we discuss a case in which a patient with metastatic renal cell carcinoma experienced exacerbation of underlying paraneoplastic dermatomyositis after treatment with ICI. He was successfully continued on ICI with the use of intravenous immunoglobulin. The patient experienced adequate control of his myositis but also experienced deepening of his antitumor response.
Source: Journal of Immunotherapy - Category: Allergy & Immunology Tags: Clinical Studies Source Type: research
In conclusion, the immune microenvironment landscape presented in this study provides a novel insight for further experimental and clinical exploration of tailored immunotherapy for patients with KIRP.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
oacute;pez Charles H. Lawrie The anti-angiogenic therapy sunitinib remains the standard first-line treatment for meta static clear cell renal cell carcinoma (ccRCC). However, acquired resistance develops in nearly all responsive patients and represents a major source of treatment failure. We used an integrated miRNA and mRNA transcriptomic approach to identify miRNA:target gene interactions involved in sunitinib resistance. Through the generation of stably resistant clones in three ccRCC cell lines (786-O, A498 and Caki-1), we identified non-overlapping miRNA:target gene networks, suggesting divergent mechanisms of s...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
ConclusionsThe seven m6A-related lncRNAs prognostic risk signature showed reliable prognostic predictive power for ccRCC and was associated with the expression of immune checkpoints and immune cell infiltration. This seven m6A-related lncRNAs signature will be helpful in managing ccRCC and guiding individualized immunotherapy.
Source: Immunity, Inflammation and Disease - Category: Allergy & Immunology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Aktuelle Urol. 2021 Sep;52(5):439-444. doi: 10.1055/a-1480-3653. Epub 2021 Aug 24.ABSTRACTRenal cell carcinoma is a common malignant tumour, whose incidence is steadily increasing. Whilst operative techniques have recently improved, including possibilities of renal preservation and minimally invasive surgery, no use has been shown for adjuvant treatment strategies. When local therapies are not suitable in relapsed or metastatic disease, medical drug treatment is indicated. The first immunologic treatment for renal cell carcinoma consisted of cytokines and overall survival amounted to a median of 13 months. Over the last de...
Source: Aktuelle Urologie - Category: Urology & Nephrology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Immunotherapy | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology